PROGNOSYS BIOSCIENCES, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): There is a need for multiplexed assay technologies th

PROGNOSYS BIOSCIENCES, INC. — SBIR Phase I award from Department of Health and Human Services.

Amount
$224,688
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Solicitation
PA12-191
NAICS
Place of performance
CA
Period

Description

DESCRIPTION (provided by applicant): There is a need for multiplexed assay technologies that enable diagnostics and detailed characterization of rheumatoid arthritis. In this project we plan to discover new rheumatoid arthritis biomarkers and implement them in a panel of multiplexed assays. We propose a novel approach that offers significant advances over existing methods, including the ability to rapidly develop, validate, and implement highly multiplexed, high- performance assays. If successful, our long-term goal is to transfer these new assays to the clinic as valuable new tools for high sensitivity diagnostics and treatment decision- making. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: We are developing multiplexed assays for rheumatoidarthritis. The assays will be useful for earlier disease detection, classification, and monitoring response to treatment. If successful, this project will improve rheumatoid arthritis diagnosis and aid therapeutic decision-making.